Ibogaine for alcohol

Trials & Access

A concise guide to the clinical trial pipeline, legal status, and realistic access pathways for ibogaine and noribogaine derivatives in the context of alcohol use disorder as of 2026.

Search registered studies

The landscape

The question is not simply whether access exists.

For alcohol use disorder, the meaningful distinctions are between monitored research, licensed prescription care where a medicine is approved, and commercial settings operating outside a person’s home regulatory system. The broader ibogaine and alcohol overview explains why uncertainty about evidence and safety should remain central to any discussion of access.

In the United States, ibogaine is listed as a Schedule I controlled substance under the federal Controlled Substances Act. The DEA’s drug scheduling information describes the federal framework; it does not make ibogaine available as a standard prescription treatment for alcohol use disorder.

Ibogaine’s active metabolite, noribogaine, has also been studied as a possible development pathway. The ibogaine reference entry provides background on the compound’s origin and pharmacology, but it should not be taken as evidence that a treatment has been established for AUD.

Trial pipeline

What to look for in a study record.

A registry entry can identify the study’s status, primary sponsor, location, inclusion and exclusion criteria, intended outcomes, and listed contacts. These details can change, so the registry record—not a clinic advertisement or an older summary—is the appropriate source for current status.

FDA acceptance of an investigational new drug program for a noribogaine candidate means a sponsor may study that candidate under the agency’s research process. It does not mean the candidate is approved, routinely prescribable, or proven effective. The FDA’s IND application guidance distinguishes investigational research from marketing authorization.

Recruitment status varies

Active or recruiting records

For active records relevant to alcohol use disorder, search ClinicalTrials.gov for AUD and ibogaine. Review the listed status, sponsor, locations, and eligibility directly before drawing conclusions about participation.

Completed records

Completed studies

Completed or terminated records may explain what was studied and whether results were posted. A completed study does not itself establish a treatment pathway, and results may be limited, unavailable, or not applicable to a different population.

Eligibility is study-specific

Enrollment criteria

Studies commonly set detailed rules about diagnosis, medical history, medication use, substance use, cardiac risk, pregnancy, and capacity to attend follow-up. Meeting a broad description online does not establish eligibility.

Three different routes

Access categories should not be blurred.

Research settings

Legitimate clinical research is governed by a protocol, oversight process, consent requirements, screening rules, and study-specific follow-up. Enrollment may be limited by geography and narrowly defined criteria. Study participation is not the same as ordinary clinical care.

Licensed prescription pathways

As of 2026, there is no licensed U.S. prescription pathway for ibogaine to treat alcohol use disorder. A research program involving noribogaine does not change that status. For context on the questions an evidence-first resource can help organize, see Kanza’s information scope.

Unregulated overseas clinics

Some people encounter commercial programs outside their home country. Their availability does not establish legality at home, clinical quality, adequate emergency preparedness, informed consent, or reliable follow-up. This page does not facilitate access to or refer people to providers.

Questions to keep open

Practical uncertainty is still uncertainty.

Search results often combine treatment marketing, research records, and personal accounts. They should be separated rather than treated as interchangeable evidence.

Does an FDA-cleared investigation mean noribogaine is approved?

No. An investigational program allows research under FDA oversight; it does not establish safety or effectiveness for routine prescribing and does not make a product approved. Pages such as what an ibogaine treatment is described as can help show how widely public language varies, but regulatory status must be checked independently.

How can trial status be checked?

Use the public registry record for the latest recruitment label, criteria, locations, sponsor, and outcome information. Older summaries can lag behind registry updates. Searches for Mexico ibogaine treatment do not replace a registered protocol or confirm that a program is a clinical trial.

Are overseas clinics equivalent to a research study?

No. A commercial or overseas setting is not automatically a regulated clinical trial and may differ substantially in oversight, screening, monitoring, emergency capacity, reporting, and follow-up. The same distinction applies to pages framed around an ibogaine clinic in Mexico or a Mexico clinic search.

Do condition-specific claims change the access picture?

No. Claims about other conditions do not establish a pathway for AUD or make an investigational compound approved. Material discussing ibogaine treatment for Parkinson’s and searches for ibogaine treatment in Texas should be considered separately from current trial eligibility and federal legal status.

A grounded next step

Keep the record, the rule, and the claim separate.

A trial registry can show what is being studied. A regulator can show what is approved or controlled. Neither one turns a commercial offering into proven care. If you are weighing claims about ibogaine and alcohol use, the safety and screening considerations are an essential companion to this access landscape.

Questions about Kanza’s purpose and approach are addressed in the organization’s mission and principles.